[参考文献]
[ 1 ] WESTLAND C, DELANDY W, YANG H, et al. Hepatitis B virusgenotypes and virologic response in 694 patients in phase III studiesof adefovir dip ivoxil1 [ J ]. Gastroenterology, 2003, 125 ( 1 ) : 107 -116.
[ 2 ] COOKSLEYW G F, P IRATV ISUTH T,LEE S D, et al. Peginterferonalpha2a ( 40kDa ) : an advance in the treatment of hepatitis Bantigen—positive chronic hepatits[ J ]. R J V iral Hepatitis, 2003, 10(2) : 298 - 305.
[ 3 ] JANSSEN H L A, VAN ZONNEVELD M , SENTURK H, et al.Pegylated interferon alfa22b alone or in combination with lamivudinefor HBeAg2po sitive chronic hepatitis B: a randomized tria1 [ J ].Lancet, 2005, 365 (1) : 123 - 129.
[ 4 ] BON INO F,MARCELL IN P, LAU G K, et al. Predicting response topeginterferon alfa22a, lamivudine and the two combined for HBeAg2negative chronic hepatitisB [ J ]. Gut, 2007, 56: 699 - 705.
[ 5 ] PAPATHEODOR ID IS G V, D IMOU E, D IMAKOPOULOS K, et al.Outcome of hepatitis B e antigen2negative chronic hepatitis B onlong2term nucleos( t) ide analog therapy startingwith lamivudine[ J ].Hepatology, 2005 , 42 (1) : 121 - 129.
[ 6 ] DELANEYW E IV, YANG H,WESTLAND C E, et al. The hepatitisB virus polymerase mutation rtV173L is selected during lamivudinetherapy and enhances viral rep lication in vitro[ J ]. J V irol, 2003 , 77(21) : 11833 - 11841.
[ 7 ] YATSUJ IH,NOGUCH I C, H IRAGA N, et al. Emergence of a novellamivudine2resistant hepatitis B virus variant with a substitutionoutside the YMDD motif[ J ]. Antim icrob Agents Chem other, 2006 , 50(11) : 3867 - 3874.
[ 8 ] ZHANG X, L IU C, GONG Q, et al. Evolution of wild type andmutants of the YMDD motif of hepatitis B virus polymerase duringlamivudine therapy [ J ]. J Gastroenterol Hepatol, 2003 , 18 ( 12 ) :1353 - 1357.
[ 9 ] MATSUDA M, SUZUKI F, SUZUKI Y, et al. YMDD mutants inpatientswith chronic hepatitisB before treatment are not selected bylamivudine[ J ]. J M ed V iol, 2004 , 74 (2) : 361 - 366.
[ 10 ] SUZANE K O, NAOYA K , YASUSH I S , et al. The polymeraseL528M mutation cooperates with nucleotide binding2site mutations,increasing hepatitis B virus rep lication and drug resistance [ J ]. JClin Invest, 2001 , 107 (4) : 449 - 455.
[ 11 ] HADZIYANN IS S J, PAPATHEODOR ID IS GV. Adefovir dip ivoxil inthe treatment of chronic hepatitis B virus infection [ J ]. Expert RevAnti Infect Ther, 2004 , 2 (4) : 475 - 483.
[ 12 ] RAPIT I,D IMOU E,M ITSOULA P, et al. Adding on versus switchingto adefovir therapy in lamivudine resistant HBeAg negative chronichepatitis B [ J ]. Hepatology, 2007 , 45 (2) : 307 - 313.
[ 13 ] HADZYANNNN IS S J, TASSOPOULOS N G, HEATHCOTE E J, etal. Long2term therapy with adefovir dip ivoxil for HBeAg2negativechronic hepatitis B [ J ]. N Engl J Med, 2005 , 352 ( 26 ) : 2673 -2681.
[ 14 ] CHANG T T, GISH R G,DEMAN R, et al. A comparison of entecavirand lamivudine for HBeAg2positive chronic hepatitisB [ J ]. N Engl JM ed, 2006, 354 (10) : 1001 - 1010.
[ 15 ] CHANG T T, GISH R G, HADZIYANN IS S J, et al. A dose2rangingstudy of the efficacy and tolerability of entecavir in lamivudine2refractory chronic hepatitis B patients [ J ]. Gastroenterology, 2005 ,129 (4) : 1198 - 1209.
[ 16 ] TENNEY D J,LEV INE SM, ROSE R E, et al. Clinical emergence ofentecavir resistant hepatitisB virus requires additional substitutions invirus already resistant to lamivudine [ J ]. Antim icrob AgentsChemother, 2004, 48 (9) : 3498 - 3507.
[ 17 ] XIONG X, YANG H,WESTLAND C E, et al. In vitro evaluation ofhepatitis B virus polymerase mutations associated with famciclovirresistance[ J ]. Hepatology, 2000, 31 ( 1 ) : 219 - 224.
[ 18 ] CHEE K H, GEORGE K K, Lau. Advances in immunomodulatingtherapy of HBV infection[ J ]. Int J M ed Sci, 2005, 2 (1) : 24 - 29.
[ 19 ] 李 莉,成 军,纪 冬,等. 抗乙型肝炎病毒的联合序贯治疗[ J ]. 世界华人消化杂志, 2004, 12 (7) : 1656 - 1658.
[ 20 ] SHERMAN M, YURDAYD IN C, SOLLANO J, et al. Entecavir fortreatment of lamivudine refractory, HBeAg positive chronic hepatitisB [ J ]. Gastroenterology, 2006 , 130 (7) : 2039 - 2049.
[ 21 ] PETERSM G, HANN H W H,MARTIN P, et al. Adefovir dip ivoxilalone or in combination with lamivudine in patients with lamivudine2resistant chronic hepatitis B [ J ]. Gastroenterology, 2004, 126 ( 1 ) :91 - 101.
[ 22 ] ZHANG X,L IU C, GONGQ, et al. Evolution ofwild type andmutantsof the YMDD motif of hepatitisB virus polymerase during lamivudinetherapy[ J ]. J Gastroenterol Hepatol, 2003, 18 (12) : 1353 - 1357.
[ 23 ] BEATR ICE S , PERR INE M , BETTINA W , et al. Effects of pyri2midine and purine analog combinations in the duck hepatitis B virusinfection model [ J ]. Antim icrob Agents Chem other, 2003, 47 ( 6 ) :1842 - 1852.
[ 24 ] AYMAN M, ABDELHAMED, COLLEEN M, et al. Rebound of hep2atitis B virus rep lication in HepG2 cells after cessation of antiviraltreatment[ J ]. J V irol, 2002, 76 (16) : 8148 - 8160.
[ 25 ] SA I,L IU X b. Development of polymeric nanoparticles in the targetingdrugs carriers[ J ]. J B iom ed Eng, 2004, 21 (3) : 495 - 497.
[ 26 ] CA I C, CA I K R, XU M Y. Synthesis and characterization of gala2ctosyl2HSA ( a hepatic targeting drug carrier) [ J ]. J Guandong M edColl, 2005, 23 (3) : 235 - 237.
[ 27 ] ZHU J J , XIE J Q ,WANG Y L , et al. Research of targeted drugpolymer conjugates[ J ]. J B iom Eng Res , 2004, 23 (4) : 249 - 252.
[ 28 ] CHEN X L,WU Z Z, FENGQ Y, et al. Current advances in the studyof the targeted anticancer drug delivery systems [ J ]. J ChongqingUniv , 2004, 27 (9) : 92 - 95.
[ 29 ] SEIGNERES B, PICHOUD C. Inhibitory activity of dioxolane purineanalogs on wild type lamivudine resistant mutants of hepadnaviruses[ J ]. Hepatology, 2002, 36 (3) : 710 - 722.
[ 30 ] SONG E, LEE S K,WANG J, et al. RNA interference targeting fasp rotectsmice from ful minant hepatitis [ J ]. N at Med, 2003, 9 ( 3) :347 - 351.
[ 31 ] SONG E W, ZHU P C, LEE S K, et al. Antibody mediated in vivodelivery of small interfering RNAs via cell surface recep tors[ J ]. N atB iot , 2005, (23) : 709 - 717.
[ 32 ] ROBACZEWSKA M,NARAYAN R, SEIGNERES B, et al. Sequence2specific inhibition of duck hepatitis B virus reverse transcrip tion bypep tide nucleic acids ( PNA) [ J ]. J Hepatol, 2005, 42 ( 2 ) : 180 -187.
